ArticleCureus2026
Effects of Sphingomyelin on Skin Conditions in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Sphingomyelin (Sph) is a bioactive phospholipid, and its ingestion is suggested to improve skin conditions. Dairy products are accessible dietary sources of Sph. We investigated the effects of dairy-derived Sph on skin conditions. Methods A randomized, double-blind, placebo-controlled trial was conducted. The participants were healthy adult women aged 30-59 years recruited in Japan, who ingested a tablet containing dairy-derived Sph (23.6 mg/day) or a placebo tablet for 12 weeks. The primary endpoints were skin hydration and transepidermal water loss (TEWL). The secondary endpoint was the subjective perception of skin hydration. Results Overall, 94 participants were enrolled and randomly assigned to two groups (placebo, n = 48; Sph, n = 46). At the end of the intervention, 84 participants remained, and 83 (placebo, n = 44; Sph, n = 39) were analyzed. The increase in skin hydration levels on the upper arm in the Sph group was higher than that in the placebo group. TEWL and subjective perception of skin hydration showed no significant differences between the two groups. The incidence of adverse events was comparable between groups, and no adverse drug reactions were found. Conclusion Intake of dairy-derived Sph is safe and improves skin hydration. Sph-rich dairy products can be used to maintain skin health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.